| Not Yet Recruiting | Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer NCT07477444 | Universitaire Ziekenhuizen KU Leuven | Phase 1 / Phase 2 |
| Not Yet Recruiting | Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative T NCT06978062 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 |
| Not Yet Recruiting | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal NCT07481357 | Dong-A ST Co., Ltd. | Phase 1 |
| Withdrawn | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants W NCT06410534 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 | Natera, Inc. | — |
| Recruiting | PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer NCT06906887 | Medical College of Wisconsin | Phase 2 |
| Withdrawn | Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) NCT06283238 | Duke University | — |
| Recruiting | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer NCT06028737 | Ukrainian Society of Clinical Oncology | Phase 2 / Phase 3 |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 | National University Hospital, Singapore | Phase 2 |
| Recruiting | Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treat NCT06468280 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer NCT06497569 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma ( NCT06356311 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unre NCT06241469 | Wu Jun | Phase 2 |
| Recruiting | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer NCT06109467 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and NCT06243757 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors NCT06171789 | Genmab | Phase 1 / Phase 2 |
| Recruiting | The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach NCT06138223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Completed | Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America NCT05924789 | Latin American Cooperative Oncology Group | — |
| Recruiting | GastrOesophageal Tumor, Immune Microenvionnment (GOTIM) NCT05644431 | Centre Leon Berard | — |
| Active Not Recruiting | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers NCT05379972 | University of Colorado, Denver | Phase 2 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Recruiting | Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) NCT05431738 | Société Française d'Endoscopie Digestive | N/A |
| Active Not Recruiting | Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) P NCT05438940 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Terminated | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT05395052 | Fate Therapeutics | Phase 1 |
| Recruiting | Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Prox NCT05205343 | M.D. Anderson Cancer Center | — |
| Completed | A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvir NCT05338060 | Inova Health Care Services | — |
| Unknown | Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma NCT05122091 | Guangxi Medical University | Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Active Not Recruiting | Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radia NCT05717998 | Ohio State University Comprehensive Cancer Center | — |
| Recruiting | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcin NCT04069273 | Harry H Yoon | Phase 2 |
| Active Not Recruiting | Supportive Oncology Care At Home RCT NCT04544046 | Massachusetts General Hospital | N/A |
| Unknown | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second NCT04555304 | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 |
| Completed | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours NCT04504669 | AstraZeneca | Phase 1 |
| Terminated | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persi NCT04510285 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal NCT04363801 | Leap Therapeutics, Inc. | Phase 2 |
| Recruiting | Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer NCT04688801 | The Second Hospital of Shandong University | N/A |
| Terminated | Early IntraVenous Administration of Nutritional Support NCT03949907 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Terminated | Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer NCT04294784 | Huazhong University of Science and Technology | Phase 2 |
| Active Not Recruiting | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma NCT04164979 | University of California, Irvine | Phase 2 |
| Completed | Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of U NCT04281576 | NovoCure Ltd. | N/A |
| Withdrawn | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer NCT03818997 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Unknown | Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and NCT04385641 | Shandong Golden Brick Biotechnology Co., Ltd. | N/A |
| Completed | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients NCT04099641 | OncXerna Theraputics, Inc. | Phase 2 |
| Completed | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma NCT04074343 | University of California, Irvine | Phase 1 |
| Terminated | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: NCT03997448 | Nataliya Uboha | Phase 2 |
| Completed | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal NCT03798626 | Novartis Pharmaceuticals | Phase 1 |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Completed | A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential NCT03813784 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Active Not Recruiting | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab NCT03610711 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Unknown | Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy NCT03613142 | Peking University Cancer Hospital & Institute | N/A |
| Completed | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors NCT03775850 | Evelo Biosciences, Inc. | Phase 1 |
| Completed | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies NCT03720678 | Arcus Biosciences, Inc. | Phase 1 |
| Completed | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untrea NCT03647969 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Active Not Recruiting | PREoperativ Study of Exercise Training NCT03490565 | Jesper Frank Christensen, PhD | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Ma NCT03629756 | Arcus Biosciences, Inc. | Phase 1 |
| Completed | Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer NCT03490292 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Completed | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastri NCT03472365 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarci NCT03409848 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly P NCT03416244 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD- NCT03321630 | NYU Langone Health | Phase 2 |
| Completed | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers NCT03279237 | Massachusetts General Hospital | Phase 1 |
| Completed | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers NCT03165994 | Apexigen America, Inc. | Phase 2 |
| Active Not Recruiting | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer NCT03044613 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) E NCT03125200 | ADC Therapeutics S.A. | Phase 1 |
| Completed | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and A NCT03013010 | Shanghai Cancer Hospital, China | Phase 3 |
| Completed | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemo NCT02853474 | Centre Oscar Lambret | Phase 3 |
| Terminated | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors NCT02669914 | Washington University School of Medicine | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combi NCT02586987 | AstraZeneca | Phase 1 |
| Completed | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal NCT02317991 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab NCT02013154 | Leap Therapeutics, Inc. | Phase 1 |
| Completed | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric NCT01715233 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated NCT01611857 | SCRI Development Innovations, LLC | Phase 1 / Phase 2 |
| Terminated | Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer NCT01145404 | National Center for Tumor Diseases, Heidelberg | Phase 2 |
| Completed | Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy( NCT00718354 | Thrombosis Research Institute | Phase 3 |
| Completed | FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer NCT00673673 | Yale University | Phase 2 |
| Terminated | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma NCT00256269 | University of California, Irvine | Phase 2 |
| Completed | Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Ca NCT00525915 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophagea NCT00080002 | Enzon Pharmaceuticals, Inc. | Phase 2 |
| No Longer Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors NCT04681248 | Leap Therapeutics, Inc. | — |